Podcast: Bridging GHD Gaps

Bridging GHD Gaps: From Complexity to Continuity (ACCME, ANCC, ACPE accredited; 1.5 CME credits)

What does continuity of care really look like in growth hormone deficiency (GHD)? In this 6‑part accredited podcast series, Bradley S. Miller (University of Minnesota Medical School, Minneapolis, USA) and leading GHD experts break down the clinical decisions shaping diagnosis, multidisciplinary care, transition, and long‑term adherence.

This accredited podcast series is designed for endocrinologists, pediatricians, endocrinology nurses, pharmacists, and all healthcare professionals involved in the care of people with GHD.

After listening to all six episodes, you can claim a total of 1.5 CME credits upon successful completion of an evaluation form. 

Important note: If you are not logged into your Medthority account, please complete the full session without exiting your browser. If you exit before finishing, you’ll need to restart from the beginning. We recommend logging in to preserve your progress if you need to pause. Not a member yet? You can set up your free account in just a few minutes.

Recognizing syndromic and secondary causes of GHD

Episode 1. What are the clinical clues for identifying syndromic and secondary causes of GHD? Lars Sävendahl joins Bradley S. Miller to address this question and discuss growth patterns, developmental features, and family history. They also consider the role of genetic testing and multidisciplinary evaluation. Sävendahl highlights how collaboration across specialties can support accurate diagnosis, timely referral, and coordinated long-term care.

Meet the experts

Bradley S. Miller, MD, PhD

Bradley S. Miller is a professor in the Department of Pediatrics and Division Director of Pediatric Endocrinology at the University of Minnesota Medical School, and Director of the Pediatric Growth Program and Pediatric Bone Clinic at M Health Fairview Masonic Children’s Hospital in Minneapolis, Minnesota, USA. He is a pediatric endocrinologist with expertise in growth disorders, bone health, adrenal function, and pubertal development, with a particular focus on rare diseases and the long-term effects of medical adversity in children.
 
Disclosures: Consultant for Amgen, Ascendis Pharma, Azurity, BioMarin, Calico, Eton Pharmaceuticals, Keenova, Novo Nordisk, Pfizer, QED/BridgeBio, Soleno, Tolmar, and Tyra; research support from Aardvark Therapeutics, AbbVie, Aeterna Zentaris, Alexion, Antares Pharma, Ascendis Pharma, BioMarin, Foresee, Foundation for Prader Willi Research, Lumos Pharma, Novo Nordisk, OPKO Health, and Pfizer.

Lars Sävendahl, MD, PhD

Lars Sävendahl is Professor and Head of the Paediatric Endocrinology Unit at Karolinska Institutet, Stockholm, Sweden, and Scientific Director at Astrid Lindgren Children’s Hospital. He is a pediatric endocrinologist with expertise in growth and bone development, and his research focuses on the hormonal regulation of bone growth and translational studies in pediatric endocrinology.

Disclosures: Consultation fees and lecture honoraria from Merck, Novo Nordisk, and Pfizer.

Mehul Dattani, MD

Mehul Dattani is Professor of Pediatric Endocrinology at the University College London (UCL) Great Ormond Street Institute of Child Health, UK, and Consultant in Pediatric Endocrinology at Great Ormond Street Hospital. He has a laboratory group investigating the molecular basis of hypothalamo-pituitary disease at UCL, working on novel genes implicated in hypothalamo-pituitary development in patients with congenital hypopituitarism as well as elucidating the molecular basis of other rare endocrine disorders. He is the current President of the European Society for Pediatric Endocrinology.

Disclosures: Faculty member of the Henning Andersen course sponsored by Novo Nordisk. Member of the steering committee for EDGE and IDEE meetings – Sandoz. Lecture honoraria from Merck Serono, Novo Nordisk, Pfizer, and Sandoz. Consultancy/advisory boards for Ferring, Pfizer, and Sandoz, and has a Neurocrine Biosciences clinical trial contract with GOSH. Participant in clinical trials sponsored by Rhythm Pharmaceuticals.

Paul Dimitri, BSc, MBChB, FRCPCH, PhD

Paul Dimitri is Professor of Child Health Technology at the University of Sheffield, UK, and a Consultant in Paediatric Endocrinology at Sheffield Children’s NHS Foundation Trust. His expertise includes growth, puberty, and endocrine disorders, with a research focus on child health technology, skeletal development, and innovation in pediatric care.

Disclosures: Honoraria from Merck for chairing e-advisory boards and presentations; research funding from NIHR UK.

LEARNER NOTIFICATION DETAILS